BLGO vs. AMTX, VGAS, FSI, TSE, LODE, ORGN, ALTO, LOOP, CBUS, and ZTEK
Should you be buying BioLargo stock or one of its competitors? The main competitors of BioLargo include Aemetis (AMTX), Verde Clean Fuels (VGAS), Flexible Solutions International (FSI), Trinseo (TSE), Comstock (LODE), Origin Materials (ORGN), Alto Ingredients (ALTO), Loop Industries (LOOP), Cibus (CBUS), and Zentek (ZTEK). These companies are all part of the "chemicals" industry.
BioLargo vs. Its Competitors
BioLargo (NASDAQ:BLGO) and Aemetis (NASDAQ:AMTX) are both small-cap chemicals companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.
In the previous week, BioLargo's average media sentiment score of 0.00 equaled Aemetis'average media sentiment score.
0.0% of BioLargo shares are owned by institutional investors. Comparatively, 27.0% of Aemetis shares are owned by institutional investors. 19.3% of BioLargo shares are owned by insiders. Comparatively, 15.9% of Aemetis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
BioLargo has higher earnings, but lower revenue than Aemetis. BioLargo is trading at a lower price-to-earnings ratio than Aemetis, indicating that it is currently the more affordable of the two stocks.
BioLargo has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Aemetis has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.
Aemetis has a consensus target price of $17.00, indicating a potential upside of 582.73%. Given Aemetis' stronger consensus rating and higher possible upside, analysts plainly believe Aemetis is more favorable than BioLargo.
BioLargo has a net margin of -11.45% compared to Aemetis' net margin of -36.70%. Aemetis' return on equity of 0.00% beat BioLargo's return on equity.
Summary
Aemetis beats BioLargo on 8 of the 14 factors compared between the two stocks.
Get BioLargo News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLGO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BLGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLargo Competitors List
Related Companies and Tools
This page (NASDAQ:BLGO) was last updated on 9/4/2025 by MarketBeat.com Staff
Free BLGO Stock Alerts